e-ISSN: Pending
Negative / Null Result ReportOpen accessImmunology and Microbiology· cited by 42

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Kalijn F. Bol; Gerty Schreibelt; Martine Bloemendal; Wouter W. van Willigen; Simone Hins-de Bree; Anna L. de Goede; Annemiek J. de Boer; Kevin Bos · 2024 · Nature Communications

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant treatment with nDCs (n = 99) or placebo (n = 49). Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall surv

Abstract by Kalijn F. Bol; Gerty Schreibelt; Martine Bloemendal; Wouter W. van Willigen; Simone Hins-de Bree; Anna L. de Goede; Annemiek J. de Boer; Kevin Bos, Nature Communications (2024) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1038/s41467-024-45358-0